Interpretation Bias Modification for Body Dysmorphic Disorder

Body Dysmorphic Disorder Clinical Trial

Official title:

Evaluation of an Internet-Based Treatment for Body Dysmorphic Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02635152
• Other study ID #: 2017.20244
• Status: Completed
• Phase: N/A
• Start date: September 2015
• Est. completion date: March 2018

Study information

• Verified date: January 2021
• Source: Florida State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a computerized intervention designed to reduce appearance and evaluation related interpretation biases will reduce symptoms associated with body dysmorphic disorder.

Description:

The present study aims to examine the feasibility of a remote treatment for body dysmorphic disorder delivered via the Internet. To evaluate the efficacy of the IBM protocol we have developed in reducing negative appearance and evaluative related interpretations, we will conduct a two-arm randomized controlled trial over the internet. Individuals with a diagnosis of body dysmorphic disorder (N = 40) will be randomized to one of two conditions: 1) IBM or 2) progressive muscle relaxation. Each condition will consist of eight 10-25 minute treatment sessions. Participants will complete two sessions per week for four weeks and will be administered assessments at pre-treatment, one week post-treatment and at 3-month follow-up. We hypothesize that: 1) IBM will lead to greater reductions in BDD symptoms than the PMR condition; 2) IBM will lead to greater reductions in depression, anxiety and suicidal ideation than the PMR condition; 3) IBM will lead to greater reductions in threat interpretations and greater increases in benign interpretations than the PMR condition; 4) The effects of condition on BDD symptoms will be mediated by changes in BDD-related interpretation bias; and 5) The effects of training in the IBM condition will be maintained at the 3-month follow-up assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 2018
• Est. primary completion date: March 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Current diagnosis of Body Dysmorphic Disorder according to DSM-5 criteria
• BDD-YBOCS score greater than or equal to 20
• Fluent in English
• No significant physical defect or flaw in appearance (e.g., disfiguration)

Exclusion Criteria:

• History of psychotic disorder, bipolar disorder, borderline personality disorder
• Current substance use disorder
• Unstable medication status (i.e. change in medication within the last month)
• Concurrent psychotherapy for appearance concerns
• Active and clinically significant suicidality

Related Conditions & MeSH terms

• Body Dysmorphic Disorder
• Body Dysmorphic Disorders

Intervention

Behavioral:
• Interpretation Bias Modification
Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
• Progressive Muscle Relaxation
Eight 15-minute sessions of progressive muscle relaxation (PMR).

Locations

Country	Name	City	State
United States	Florida State University Psychology Department	Tallahassee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Florida State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS; Phillips et al., 1997)	Measures past-week BDD symptom severity	change from baseline at one-week post treatment and 3-months post-treatment
Secondary	Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996)	Measures depressive symptom severity	change from baseline at one-week post treatment and 3-months post-treatment
Secondary	Beck Anxiety Inventory (BAI; Steer & Beck, 1997)	Measure anxious symptom severity	change from baseline at one-week post treatment and 3-months post-treatment
Secondary	Depressive Symptom Index-Suicidality Subscale	Measure severity of recent suicidality	change from baseline at one-week post treatment and 3-months post-treatment
Secondary	Body Dysmorphic Disorder Word Sentence Association Paradigm (BDD-WSAP; modified from Hindash & Amir, 2011)	Measure of strength of BDD-related (i.e. evaluation- and appearance- related threat interpretation biases)	change from baseline at one-week post treatment and 3-months post-treatment